Anavex Life Sciences

AVXLNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$309.524 M

$3.34 +1.83%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$46.4M

Loss-making

Shares outstanding

89,348,107

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#85Inhibikase TherapeuticsIKT$326.1M
#86AgenusAGEN$311.5M
#87Anavex Life SciencesAVXL$309.5M
#88Neumora TherapeuticsNMRA$302.0M
#89SAB BiotherapeuticsSABS$298.2M

Where these numbers come from

Share counts and financials for Anavex Life Sciences are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.